AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amneal Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$19.36+0.18 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $6.35B
- P/E (TTM)
- 39.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
36.9%+5.3 pts over 5 years
Operating margin
13.1%+8.5 pts over 5 years
Net margin
2.4%−1.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8.0% | +10.9% | +8.7% | – | |
| Gross profit | +9.1% | +12.4% | +12.1% | – | |
| Operating income | +58.1% | – | +34.0% | – | |
| Net income | – | – | +1.2% | – | |
| EPS, diluted | – | – | -18.5% | – | |
| Free cash flow | +11.0% | +143.5% | -3.5% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 25.3% | -80.0% | |
| Return on assets | – | 1.8% | 2.0% | |
| Current ratio | – | 2.29 | 2.17 | |
| Debt to equity | – | 9.17 | -36.33 | |
| Inventory turnover | – | 3.1× | 3.1× | |
| Capex to revenue | 12.1% | 2.8% | 2.3% | |
| Diluted shares | – | 149M | 325M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Amneal Pharmaceuticals generated $1.29B from operations and spent $259.34M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.29B
Used
$259.34M
Capital expenditure$259.34M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin2.4%
×Asset turnover0.84×
×Equity multiplier-39.87×
=Return on equity, FY2025-80.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 2.4% | 0.84× | -39.87× | -80.0% |
| FY2024 | -4.2% | 0.80× | -77.93× | 261.2% |
| FY2023 | -3.5% | 0.66× | 22.85× | -52.8% |
| FY2022 | -12.2% | 0.57× | 11.75× | -82.1% |
| FY2021 | 0.6% | 0.53× | 11.97× | 4.0% |
| FY2020 | 3.4% | 0.52× | 14.33× | 25.3% |
| FY2019 | -37.1% | 0.41× | 10.88× | -163.8% |
| FY2018 | -1.2% | 0.58× | 11.28× | -7.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$72.06M
- Cash generatingOperating cash flow above zero$339.99M
- Return on assets improvedROA up on the prior year-3.4% → 2.1%
- Earnings backed by cashOperating cash flow above net income$339.99M vs $72.06M
- Less leverageLong-term debt to assets fell61.7% → 69.7%
- Better liquidityCurrent ratio rose1.41 → 2.17
- No dilutionShare count did not rise309M → 325M
- Gross margin improvedGross margin up on the prior year36.52% → 36.88%
- More efficientAsset turnover rose0.80 → 0.86